Clinical Trials Directory

Trials / Unknown

UnknownNCT02902393

Interest of Thromboelastography (ROTEM) as a Biomarker of Revascularisation in Stroke

Status
Unknown
Phase
Study type
Observational
Enrollment
64 (estimated)
Sponsor
University Hospital, Caen · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Revascularisation using recombinant tPA is the reference treatment of stroke. However, the efficacy of fibrinolysis is about 50%. Several factors, including the size of thrombus, have been associated with revascularisation efficacy. The aim of this prospective study is to evaluate ex vivo the effect of tPA in patients with stroke with thromboelastography and to correlate results with the clinical outcome of patients. Results may predict revascularisation in patients with stroke.

Conditions

Interventions

TypeNameDescription
BIOLOGICALThromboelastography

Timeline

Start date
2016-07-01
Primary completion
2018-06-01
Completion
2018-09-01
First posted
2016-09-15
Last updated
2016-09-15

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02902393. Inclusion in this directory is not an endorsement.

Interest of Thromboelastography (ROTEM) as a Biomarker of Revascularisation in Stroke (NCT02902393) · Clinical Trials Directory